The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The real-world effectiveness of venetoclax-based therapy after BTKis in patients with CLL
Nilanjan Ghosh, MD, PhD, Levine Cancer Institute, Charlotte, NC, discusses the real-world effectiveness of venetoclax-based therapy after BTK inhibitors (BTKis) in patients with chronic lymphocytic leukemia (CLL). This analysis found an overall response rate (ORR) of 80%, which was slightly higher when venetoclax was used in the second line compared to later lines and in patients who had discontinued BTKis due to intolerance rather than disease progression. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: AstraZeneca, Pharmacyclics, Janssen, Bristol Myers Squibb, Gilead Sciences, Kite Pharma, BeiGene, Incyte, Lava Therapeutics, Incyte, Roche/Genentech, Novartis, Loxo Oncology, AbbVie, Genmab, Adaptive Biotech, ADC Therapeutics; Research funding: Roche/Genentech, Bristol Myers Squibb, Gilead, Morphosys, AbbVie, Pharmacyclics.
